ADMELOG SOLOSTAR

Peak

insulin lispro

BLASUBCUTANEOUSSOLUTION
Approved
Dec 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

analogs, including insulin lispro products. Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis and enhance protein synthesis.

Pharmacologic Class:

Insulin Analog

Clinical Trials (5)

NCT05262387Phase 1Completed

A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes

Started Feb 2022
25 enrolled
Diabetes Mellitus, Type 1
NCT04537923Phase 3Completed

A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin

Started Oct 2020
1,428 enrolled
Type 2 Diabetes
NCT04276207Phase 1Completed

A Study of LY900014 Versus Insulin Lispro (Humalog) on High Blood Sugar in Participants With Type 1 Diabetes Who Use Insulin Pumps

Started Feb 2020
32 enrolled
Diabetes Mellitus, Type 1
NCT03952130Phase 3Completed

A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes

Started May 2019
354 enrolled
Type 1 Diabetes Mellitus
NCT03952143Phase 3Completed

A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes

Started May 2019
628 enrolled
Type 2 Diabetes Mellitus